Cipla received India Permit to Sell COVID-19 Drug Favipiravir
Cipla Ltd has acquired Indian regulatory approval to sell anti-viral drug favipiravir to treat the virus COVID-19, the Cipla told on Friday, as coronavirus infections in the world’s third worst-hit nation show no indication of abating. The Drug Controller General of India allowed Cipla accelerated approval to create and sell favipiravir to meet the “urgent…